- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Novartis ends ALS program after phase 2 flop, adding to R&D woes | ||
| Mi | Novartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier | ||
| Di | FDA launches pilot program to speed up sluggish phase 1 trials | ||
| Di | Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope | ||
| Di | Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech | ||
| Di | Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail | ||
| Di | GSK doubles down on Chimagen with $750M multiple myeloma wager | ||
| Di | Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis | ||
| Di | J&J's Contineum-partnered depression drug flunks another phase 2 test | ||
| Mo | Lilly cans early experimental obesity drug after 'high bar' not met | ||
| Mo | Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi | ||
| Mo | Electra aims for $342M IPO to power inflammatory drug's push through phase 3 | ||
| Mo | Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon | ||
| Mo | Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival | ||
| Fr | FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer | ||
| Fr | The future of RAS inhibitors | ||
| 10.09. | Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal | ||
| 10.09. | Frazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechs | ||
| 10.09. | Takeda's long-serving R&D chief Andy Plump to retire in wake of pipeline successes | ||
| 09.09. | Luma locks down 15-year, $410M fund for life science investments | ||
| 09.09. | Google-backed Encoded gains $275M to advance Dravet drug, scale genetic med manufacturing | ||
| 09.09. | Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy | ||
| 09.09. | Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock | ||
| 09.09. | Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2 | ||
| 09.09. | Beeline flies into phase 3 as oral lupus drug soars past placebo |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.